BSE Live
Apr 20, 16:00Prev. Close
3559.80
Open Price
3614.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 20, 15:57Prev. Close
3559.80
Open Price
3580.00
Bid Price (Qty.)
3578.30 (194)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Sanofi India (in Rs. Cr.) | Dec 24 | Dec 23 | |
| 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 562.40 | 845.50 | |
| Net CashFlow From Operating Activities | 461.50 | 230.40 | |
| Net Cash Used In Investing Activities | -19.20 | 37.50 | |
| Net Cash Used From Financing Activities | -392.40 | -878.30 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | -160.60 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -110.70 | -610.40 | |
| Cash And Cash Equivalents Begin of Year | 394.50 | 1,004.90 | |
| Cash And Cash Equivalents End Of Year | 283.80 | 394.50 |
05.03.2026
Sanofi India Standalone December 2025 Net Sales at Rs 419.80 crore, down 18.47% Y-o-Y
26.02.2026
03.11.2025
Sanofi India Standalone September 2025 Net Sales at Rs 475.40 crore, down 9.27% Y-o-Y
01.08.2025
05.03.2026
Sanofi India Standalone December 2025 Net Sales at Rs 419.80 crore, down 18.47% Y-o-Y
03.11.2025
Sanofi India Standalone September 2025 Net Sales at Rs 475.40 crore, down 9.27% Y-o-Y
15.05.2025
Sanofi India Standalone March 2025 Net Sales at Rs 535.90 crore, down 26.83% Y-o-Y
17.03.2025
Sanofi India Consolidated December 2024 Net Sales at Rs 514.90 crore, down 25.8% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth